What Do Wall Street Analysts Think of Moderna?

Shares of Moderna fell to $151.01 during today's evening trading session. Despite the -2.4% change, the Large-Cap Biotechnology company still trades 6.2% above its average analyst target price of $142.2. So there may be further downside for the Biotechnology stock. Moderna has target prices ranging from $62.0 to $310.0 per share, and its average rating is buy.

Moderna has an average level of shares sold short, at 7.4% of its total share float. The stock's short ratio (also called days to cover) is 6.26. The company's insiders own 9.58% of its outstanding shares, which indicates a strong alignment between management and shareholder interests.

Institutional investors own 73.4% of Moderna's shares, which indicates they have a high level of confidence in the company.

Institutions Invested in Moderna

Date Reported Holder Percentage Shares Value
2024-03-31 Baillie Gifford and Company 12% 44,655,817 $6,743,474,679
2024-03-31 Vanguard Group Inc 10% 39,036,872 $5,894,957,826
2024-03-31 Blackrock Inc. 7% 25,395,878 $3,835,031,397
2024-03-31 State Street Corporation 4% 14,452,035 $2,182,401,725
2024-03-31 FMR, LLC 4% 13,599,837 $2,053,711,310
2024-03-31 Flagship Pioneering Inc. 3% 9,666,038 $1,459,668,345
2024-03-31 Theleme Partners LLP 2% 7,321,797 $1,105,664,524
2024-03-31 Geode Capital Management, LLC 2% 6,750,479 $1,019,389,796
2024-03-31 Wellington Management Group, LLP 1% 5,604,703 $846,366,169
2024-03-31 Morgan Stanley 1% 5,493,965 $829,643,624
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.